56 completed, 8 recruiting, 7 terminated, 6 withdrawn. 85 Phase 3, 5 Phase 2.
Follow Eczema: new trials by email Literature Review of Eczema trials Research Report on Eczema
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Abrocitinib Treatment of Atopic Dermatitis in Children 2 to Less Than 6 Years of Age Abrocitinib, Placebo - Atopic Dermatitis | Phase 3 | Not yet recruiting | Pfizer | 90 | 2027-05-01 | 2026-09-16 |
| Roflumilast Cream 0.3% for Moderate to Severe Atopic Dermatitis Roflumilast Cream 0.3%, Vehicle Cream - Atopic Dermatitis, Atopic Dermatitis (AD) | Phase 3 | Recruiting | Arcutis Biotherapeutics, Inc. | 415 | 2026-10-30 | 2026-11-06 |
| A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema Tilrekimig, Dupilumab, Placebo for Tilrekimig - Atopic Dermatitis | Phase 3 | Recruiting | Pfizer | 1375 | 2026-08-24 | 2026-11-06 |
| A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe Eczema Tilrekimig, Placebo - Atopic Dermatitis | Phase 3 | Recruiting | Pfizer | 375 | 2026-08-17 | 2026-11-12 |
| A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis Tapinarof cream, 1%, Vehicle Cream - Atopic Dermatitis | Phase 3 | Active not recruiting | Organon and Co | 187 | 2025-12-29 | 2026-11-10 |
| A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema Abrocitinib - Atopic Dermatitis | Phase 3 | Recruiting | Pfizer | 450 | 2025-12-02 | 2026-11-05 |
| A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema Abrocitinib, Placebo - Eczema | Phase 3 | Active not recruiting | Pfizer | 151 | 2025-07-24 | 2026-11-12 |
| A Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema) GX-03, Vehicle - Eczema Atopic Dermatitis, Eczema | Phase 2 / Phase 3 | Recruiting | Turn Therapeutics | 190 | 2025-07-11 | 2026-09-04 |
| Herbal Ointment in Treating Atopic Dermatitis Topically herbal ointment, Placebo - Atopic Dermatitis, Atopic Dermatitis (AD) | Phase 2 / Phase 3 | Recruiting | En Chu Kong Hospital | 66 | 2025-03-01 | 2025-02-27 |
| VItamin D in pregnanCy for prevenTion Of eaRlY Childhood Asthma Cholecalciferol D3, Olive oil - Asthma, Respiratory Tract Infections | Phase 3 | Recruiting | Professor Klaus Bønnelykke | 2000 | 2024-12-20 | 2025-09-30 |
| Fish Oil in pREgnancY for Personalized Prevention of Early Childhood Asthma n-3 fatty acid, Rape seed oil - Asthma, Respiratory Tract Infections | Phase 3 | Recruiting | Professor Klaus Bønnelykke | 2000 | 2024-12-20 | 2025-09-30 |
| A Study of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis Lebrikizumab, Placebo - Dermatitis, Atopic, Eczema | Phase 3 | Active not recruiting | Almirall, S.A. | 520 | 2024-07-03 | 2026-04-21 |
| Lebrikizumab Pen Ease of Use in Participants With Atopic Dermatitis Lebrikizumab Pen - Atopic Dermatitis | Phase 3 | Completed | Eli Lilly and Company | 55 | 2024-06-04 | 2025-07-29 |
| A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis Ruxolitinib Cream, Vehicle Cream - Atopic Dermatitis | Phase 3 | Completed | Incyte Corporation | 241 | 2024-04-26 | 2026-10-15 |
| Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis Lebrikizumab - Atopic Dermatitis, Eczema | Phase 3 | Completed | Almirall, S.A. | 260 | 2023-11-20 | 2026-07-17 |
| A Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Delgocitinib Cream in Chinese Adults and Adolescents With Moderate to Severe Chronic Hand Eczema Delgocitinib, Vehicle cream - Chronic Hand Eczema | Phase 3 | Completed | LEO Pharma | 362 | 2023-09-05 | 2025-09-25 |
| A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) Rocatinlimab, Placebo - Atopic Dermatitis | Phase 3 | Terminated | Amgen | 2621 | 2023-05-31 | 2026-07-16 |
| A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis Lebrikizumab, Placebo - Atopic Dermatitis, Eczema | Phase 3 | Enrolling by invitation | Eli Lilly and Company | 338 | 2023-03-09 | 2026-10-26 |
| A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD) Rocatinlimab, Placebo - Atopic Dermatitis | Phase 3 | Completed | Amgen | 746 | 2023-02-21 | 2026-08-06 |
| Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 2 Ruxolitinib cream, Vehicle - Chronic Hand Eczema (CHE) | Phase 3 | Withdrawn | Incyte Corporation | 2023-01-31 | 2022-11-10 |
Showing 20 of 85. Sign in to see all of them.
Dermatitis, Atopic (72) · Dermatitis (27) · Skin Diseases (22) · Pruritus (12) · Hypersensitivity (10) · Skin Diseases, Eczematous (10) · Skin Diseases, Genetic (9) · Immune System Diseases (8) · Genetic Diseases, Inborn (6) · Hypersensitivity, Immediate (6) · Asthma (3) · Infections (3) · Respiratory Tract Infections (3) · Croup (2)
Skin and Connective Tissue Diseases (85) · Skin Diseases, Eczematous (75) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (72) · Hypersensitivity, Immediate (69) · Immune System Diseases (68) · Genetic Diseases, Inborn (66) · Hypersensitivity (66) · Skin Diseases (63) · Skin Diseases, Genetic (63) · Dermatitis (58) · Pathological Conditions, Signs and Symptoms (14) · Signs and Symptoms (14) · Skin Manifestations (12) · Respiratory Tract Diseases (4) · Bronchial Diseases (3)
lebrikizumab (14) · abrocitinib (9) · baricitinib (8) · dupilumab (8) · Adrenal Cortex Hormones (6) · Alitretinoin (2) · Betamethasone (2) · Desonide (2) · Exercise (2) · BCG Vaccine (1) · Benzocaine (1) · Cetirizine (1) · Clioquinol (1) · EpiCeram (1) · Fatty Acids, Omega-3 (1)
Eli Lilly and Company (20) · Pfizer (14) · Incyte Corporation (6) · Organon and Co (5) · Regeneron Pharmaceuticals (5) · Almirall, S.A. (3) · Amgen (3) · EMS (2) · LEO Pharma (2) · Merz North America, Inc. (2) · Pierre Fabre Medicament (2) · Professor Klaus Bønnelykke (2) · Vanda Pharmaceuticals (2) · Agentschap NL (1) · Arcutis Biotherapeutics, Inc. (1)
United States (50) · Canada (35) · Poland (35) · Germany (32) · Spain (24) · Australia (21) · Japan (20) · Czechia (17) · Taiwan (16) · France (15) · Hungary (15) · United Kingdom (15) · Mexico (14) · South Korea (13) · Bulgaria (12)
Diana Villalobos (3) · Bo Chawes, PhD (2) · Haq Nawaz, MD (2) · Michael E. Kuligowski, MD, PhD, MBA (2) · Michael Kuligowski, MD, PhD, MBA (2) · Adrian J Lowe, Doctorate (1)
PMID 33826132, PMID 42162528, PMID 34406619, PMID 36255569, PMID 39588375, PMID 36749121, PMID 38896380, PMID 39104653, PMID 40028832, PMID 34275122, PMID 34688290, PMID 35342978, PMID 38777187, PMID 40383273, PMID 40600584, PMID 40993471, PMID 41206702, PMID 42365219, PMID 33222559, PMID 33481203, PMID 33658996, PMID 33899152, PMID 33954933, PMID 33957195, PMID 33982267, PMID 34270797, PMID 34427891, PMID 34743361, PMID 35061234, PMID 35462428, PMID 35567671, PMID 35763326, PMID 36264430, PMID 36920778, PMID 36994947, PMID 37750994, PMID 37949351, PMID 37988255, PMID 38679419, PMID 38698175, PMID 38700646, PMID 38743155, PMID 38922484, PMID 39002092, PMID 39123054, PMID 39249591, PMID 39375281, PMID 39546129, PMID 39740942, PMID 39777610
2018 (7), 2019 (6), 2023 (6), 2017 (5), 2015 (2), 2016 (2), 2014 (1), 2025 (1)